Share This Page
Suppliers and packagers for FALLBACK SOLO
✉ Email this page to a colleague
FALLBACK SOLO
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | FALLBACK SOLO | levonorgestrel | TABLET;ORAL | 201446 | ANDA | Syzygy Healthcare Solutions, LLC PO Box 588, Westport, CT 06880 | 64122-605-01 | 1 TABLET in 1 BLISTER PACK (64122-605-01) | 2017-09-14 |
| Lupin Ltd | FALLBACK SOLO | levonorgestrel | TABLET;ORAL | 201446 | ANDA | NuCare Pharmaceuticals,Inc. | 68071-4294-1 | 1 TABLET in 1 BOX (68071-4294-1) | 2017-04-25 |
| Lupin Ltd | FALLBACK SOLO | levonorgestrel | TABLET;ORAL | 201446 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-852-11 | 1 BLISTER PACK in 1 CARTON (68180-852-11) / 1 TABLET in 1 BLISTER PACK | 2017-04-25 |
| Lupin Ltd | FALLBACK SOLO | levonorgestrel | TABLET;ORAL | 201446 | ANDA | Proficient Rx LP | 71205-361-01 | 1 BLISTER PACK in 1 CARTON (71205-361-01) / 1 TABLET in 1 BLISTER PACK | 2017-04-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: FALLBACK SOLO
Introduction
Identifying dependable suppliers for pharmaceutical drugs is critical for ensuring continuity of supply, regulatory compliance, and quality management. The drug FALLBACK SOLO appears to be a specialized or proprietary pharmaceutical product, possibly used in niche therapeutic areas or with recent market entry. As with any pharmaceutical entity, sourcing involves navigating patents, manufacturing capabilities, regulatory approvals, and distribution logistics. This analysis delineates the landscape of suppliers—both current and potential—for FALLBACK SOLO, providing strategic insights for stakeholders.
Understanding the Drug: FALLBACK SOLO
Before outlining supplier options, it is essential to contextualize FALLBACK SOLO. Given the name, it might refer to a medication used in critical care, emergency settings, or as a component within combination therapies. The drug could be either a small molecule, biologic, or advanced therapy, influencing supplier type and sourcing strategy.
Note: Due to limited publicly available data on FALLBACK SOLO, assumptions are based on typical pharmaceutical supply chain models and industry practices. If FALLBACK SOLO is a novel or proprietary compound, relevant suppliers likely include patented manufacturers, specialized biotech firms, and authorized licensors.
Regulatory and Patent Landscape
An initial step in supplier identification is comprehension of intellectual property status and regulatory approvals. For newly developed drugs, patent holders often control manufacturing rights and distribution. If FALLBACK SOLO is under patent, licensed manufacturers are typically official suppliers. Upon patent expiration, generic or biosimilar producers may enter the market, expanding supplier options.
Regulatory oversight under bodies such as the FDA (U.S.), EMA (Europe), or other regional agencies determines approved manufacturers and supply chain legitimacy. Only suppliers with authorized manufacturing site approvals ensure compliance with standards such as Good Manufacturing Practice (GMP).
Types of Suppliers for FALLBACK SOLO
1. Original Equipment Manufacturers (OEMs)
OEMs, often linked to patent holders, are primary suppliers during the drug’s initial market phase. These companies invest in high-capital manufacturing facilities, ensuring product quality and compliance. Key attributes:
- Authorized and licensed manufacturing for FALLBACK SOLO
- GMP-certified facilities
- Supply reliability due to contractual agreements
Potential OEMs: Major pharmaceutical firms with expertise in niche or complex therapeutics, such as Pfizer, Merck, or Johnson & Johnson, depending on the drug’s sophistication and origin. If FALLBACK SOLO is licensed from a biotech startup or university spin-off, the licensor becomes a critical supplier.
2. Contract Manufacturing Organizations (CMOs)
CMOs provide specialized manufacturing services, allowing patent holders or big pharma companies to outsource production. CMOs can scale manufacturing according to demand, maintain quality, and reduce costs.
- Key players: Lonza, Samsung Biologics, Patheon (Thermo Fisher), WuXi AppTec, and Boehringer Ingelheim.
- Role: Multi-purpose or specialized synthesis, formulation, fill-finish, or biologic production.
3. Generic and Biosimilar Manufacturers
Once patent exclusivity lapses, a broader supplier base emerges, boosting market competition and supply security.
- Generic firms primarily produce small molecules, often at lower costs.
- Biosimilar manufacturers produce biologic equivalents, which could be relevant if FALLBACK SOLO is biologic or biosimilar.
4. Regional and Local Suppliers
Depending on global pharma distribution strategies, regional suppliers may produce FALLBACK SOLO under licensing agreements. This approach reduces supply chain risk and facilitates local market access.
Supply Chain Considerations
- Global Supply Chains: Major pharma companies often rely on geographically diversified suppliers, ensuring redundancy.
- Quality and Compliance: Suppliers must meet GMP standards, and audits are vital in partnership selection.
- Capacity and Scalability: Manufacturing capacity must align with demand projections.
- Intellectual Property: Licensing agreements and patent protections influence supplier licensing rights.
Current Market Players and Potential Suppliers
Given limited information on FALLBACK SOLO, the following entities could be potential suppliers based on industry trends:
| Supplier Type | Notable Companies | Role | Relevance |
|---|---|---|---|
| OEMs | Pfizer, Merck, Johnson & Johnson | Licensed manufacturers | Priority suppliers if licensed |
| CMOs | Lonza, WuXi, Samsung Biologics | Contract manufacturing | Flexible capacity providers |
| Biosimilar firms | Sandoz, Biocon, Celltrion | Biosimilar production | If biologic or biosimilar |
| Regional manufacturers | Various local pharma firms | Supplementary supply | Regional distribution |
Emerging Trends Influencing Supplier Selection
- Digital Supply Chain Management: Use of digital platforms (e.g., Track & Trace) to monitor supply chain integrity.
- Regulatory Harmonization: Streamlining approval processes encourages international supplier access.
- Risk Management: Dual sourcing strategies mitigate country-specific risks, geopolitical influences, and supply disruptions.
Strategic Sourcing Recommendations
- Prioritize licensed OEMs for primary, compliant supply.
- Establish relationships with reputable CMOs to ensure scalability.
- Monitor patent landscapes—expiring patents may open licensing opportunities for new suppliers.
- Engage regional manufacturers to strengthen supply chain resilience.
- Implement robust quality audits and compliance checks.
Key Challenges in Supplier Identification
- Limited transparency: Proprietary or confidential supply arrangements.
- Regulatory restrictions: Some markets restrict manufacturing origins.
- Supply chain complexity: Biologics, complex formulations demand specialized manufacturers.
- Market exclusivity: Patent protections can limit licensing options.
Conclusion
Identifying reliable suppliers for FALLBACK SOLO hinges on understanding its patent and regulatory landscape, the nature of the pharmaceutical formulation, and strategic market considerations. The landscape encompasses OEMs holding licensing rights, CMOs providing flexible manufacturing, and potential entrants post-patent expiry. Ensuring high standards in GMP, geographic diversification, and proactive risk mitigation remain essential to maintaining a stable supply.
Key Takeaways
- Primary suppliers are typically licensed OEMs with GMP-certified manufacturing facilities.
- Contract manufacturing organizations offer scalable, specialized production, vital during demand fluctuations.
- Post-patent expiry broadens supplier options to generic and biosimilar manufacturers.
- Regulatory compliance and quality assurance are non-negotiable criteria in supplier selection.
- Global diversification of suppliers minimizes supply chain risks and enhances resilience.
Frequently Asked Questions (FAQs)
1. How can I verify the authenticity of a supplier claiming to produce FALLBACK SOLO?
Ensure the supplier holds valid GMP certifications from recognized regulatory agencies and has undergone thorough audits. Request certification documentation, manufacturing licenses, and visit facilities if necessary.
2. What factors should influence the choice between OEMs and CMOs for FALLBACK SOLO?
Consider the company's manufacturing expertise, capacity, quality standards, compliance track record, and strategic long-term partnerships. OEMs are suitable for proprietary, licensed production, while CMOs offer flexibility and scalability.
3. Are regional suppliers a viable alternative for FALLBACK SOLO?
Yes, regional suppliers can reduce logistics costs, improve supply responsiveness, and diversify risk. However, their GMP compliance and quality standards must align with global regulatory requirements.
4. How does patent expiration affect the supplier landscape for FALLBACK SOLO?
Patent expiry opens the market for biosimilars or generics, expanding the supplier pool and potentially reducing costs. It also invites new manufacturers into the competitive landscape.
5. What risks are associated with sole-source suppliers for FALLBACK SOLO?
Dependence on a single source can lead to supply disruptions due to manufacturing issues, regulatory setbacks, or geopolitical factors. Diversification and contingency planning are essential.
Sources:
- PharmSource, "Pharmaceutical Manufacturing and Supply Chain Strategies," 2022.
- U.S. Food and Drug Administration, "Drug Establishments Current Registration Site," 2023.
- Deloitte, "The Future of Pharma Supply Chains," 2022.
- EvaluatePharma, "Global Market Data," 2023.
- WHO, "Good Manufacturing Practice (GMP) Guidelines," 2020.
More… ↓
